glp 1 and dual glp 1 gip receptor agonists The Emerging Role of GLP-1 in Glycemic Management and Cardiovascular Risk Reduction Oral GLP-1-Based Therapeutics in the

Amgens MariTide leads the GLP-1 obesity therapy market in 2025 with innovative design, Phase-3 trials, and strong potential for effective weight loss.

This probiotic is designed for adults seeking daily gut health support as part of a wellness routine that includes balanced nutrition and an active lifestyle

Janet Klein, MS RDN, CDN, CDCES, Bariatric Surgery and Obesity Medicine Program Director

We report an unusual case of diabetic ketoalkalosis, a mixed acid-base disorder, in a 57-year-old female patient with insulin-dependent T2DM following a switch to Mounjaro (tirzepatide)

However, further research is needed to fully understand how these therapies exert their effect on body weight and in the last section we cover open questions about the potential mechanisms of multiagonist drugs, and the understanding of how gutbrain communication can be leveraged to achieve sustained body weight loss without adverse effects.

A 3-step daily protocol featuring prebiotics, soluble fiber, and targeted botanicals